中国当代医药
中國噹代醫藥
중국당대의약
PERSON
2014年
28期
14-16
,共3页
血管紧张素-(1-7)%慢性心力衰竭%心肌重构%血流动力学
血管緊張素-(1-7)%慢性心力衰竭%心肌重構%血流動力學
혈관긴장소-(1-7)%만성심력쇠갈%심기중구%혈류동역학
Angiotensin-(1-7)%Chronic heart failure%Myocardial remodeling%Hemodynamic
目的：探讨血管紧张素-(1-7)[Ang-(1-7)]及贝那普利对大鼠慢性心力衰竭(CHF)后心肌重构及心功能的影响。方法制作CHF模型雄性SD大鼠45只，随机分CHF组、Ang-(1-7)治疗组、Ang-(1-7)及贝那普利联合治疗组，另设15只为正常对照组，给药4周后检测血流动力学及心功能参数，检测大鼠心脏左室重量、左室重量指数及左室截面直径。结果与正常对照组比较，CHF组左室重量及左室重量指数、左室截面直径明显增大(P<0.01)，左室收缩压及左室内压最大上升和下降速率下降(P<0.01)；与CHF组比较，Ang-(1-7)治疗组左室重量及左室重量指数、左室截面积直径减小(P<0.01)，左室收缩压及左室内压最大上升和下降速率升高(P<0.01)；与Ang-(1-7)治疗组比较，联合用药组左室重量及左室重量指数、左室截面积直径减小(P<0.05)，左室收缩压及左室内压最大上升和下降速率升高(P<0.01))。结论 Ang-(1-7)可以改善CHF后心肌重构，与贝那普利联合应用改善CHF后心肌重构的作用更明显。
目的：探討血管緊張素-(1-7)[Ang-(1-7)]及貝那普利對大鼠慢性心力衰竭(CHF)後心肌重構及心功能的影響。方法製作CHF模型雄性SD大鼠45隻，隨機分CHF組、Ang-(1-7)治療組、Ang-(1-7)及貝那普利聯閤治療組，另設15隻為正常對照組，給藥4週後檢測血流動力學及心功能參數，檢測大鼠心髒左室重量、左室重量指數及左室截麵直徑。結果與正常對照組比較，CHF組左室重量及左室重量指數、左室截麵直徑明顯增大(P<0.01)，左室收縮壓及左室內壓最大上升和下降速率下降(P<0.01)；與CHF組比較，Ang-(1-7)治療組左室重量及左室重量指數、左室截麵積直徑減小(P<0.01)，左室收縮壓及左室內壓最大上升和下降速率升高(P<0.01)；與Ang-(1-7)治療組比較，聯閤用藥組左室重量及左室重量指數、左室截麵積直徑減小(P<0.05)，左室收縮壓及左室內壓最大上升和下降速率升高(P<0.01))。結論 Ang-(1-7)可以改善CHF後心肌重構，與貝那普利聯閤應用改善CHF後心肌重構的作用更明顯。
목적：탐토혈관긴장소-(1-7)[Ang-(1-7)]급패나보리대대서만성심력쇠갈(CHF)후심기중구급심공능적영향。방법제작CHF모형웅성SD대서45지，수궤분CHF조、Ang-(1-7)치료조、Ang-(1-7)급패나보리연합치료조，령설15지위정상대조조，급약4주후검측혈류동역학급심공능삼수，검측대서심장좌실중량、좌실중량지수급좌실절면직경。결과여정상대조조비교，CHF조좌실중량급좌실중량지수、좌실절면직경명현증대(P<0.01)，좌실수축압급좌실내압최대상승화하강속솔하강(P<0.01)；여CHF조비교，Ang-(1-7)치료조좌실중량급좌실중량지수、좌실절면적직경감소(P<0.01)，좌실수축압급좌실내압최대상승화하강속솔승고(P<0.01)；여Ang-(1-7)치료조비교，연합용약조좌실중량급좌실중량지수、좌실절면적직경감소(P<0.05)，좌실수축압급좌실내압최대상승화하강속솔승고(P<0.01))。결론 Ang-(1-7)가이개선CHF후심기중구，여패나보리연합응용개선CHF후심기중구적작용경명현。
Objective To investigate the influence of angiotensin-(1-7) [Ang-(1-7)] and benazepril on the myocardial re-modeling and cardiac function of rats with chronic heart failure. Methods Chronic heart failure (CHF) model of 45 male SD rats was built and the rats were randomly divided into the CHF group,the Ang-(1-7) treatment group and the Ang-(1-7) and benazepril combination treatment group.And 15 normal rats were assigned to the control group.After 4 weeks of administration,the hemodynamic and cardiac function parameters were detected and the left ventricular weight,left ventricular mass index and left ventricular cross-sectional diameter of the rats were detected. Results Compared to the normal control group,the left ventricular weight,left ventricular mass index and left ventricular cross-sectional diameter of the CHF group increased significantly (P<0.01) and the left ventricular systolic pressure and left ventricular pressure maximum rise and fall rates decreased (P<0.01).Compared to the CHF group,the left ventricular weight,left ventricular mass index and left ventricular cross-sectional diameter of the Ang-(1-7) treatment group decreased significantly (P<0.01) and the left ventricular systolic pressure and left ventricular pressure maximum rise and fall rates increased (P<0.01).Compared to the Ang-(1-7) treatment group,the left ventricular weight,left ventricular mass index and left ven-tricular cross-sectional diameter of the combination treatment group decreased significantly (P<0.05) and the left ven-tricular systolic pressure and left ventricular pressure maximum rise and fall rates increased (P<0.01). Conclusion Ang-(1-7) can improve the cardiac remodeling of CHF and its cardiac remodeling effect is more obvious when com-bined with benazepril.
